Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
In this medfyle
SGLT2 inhibitors, such as empagliflozin, can reduce hospitalisation for HF by up to 40%. This study explored whether empagliflozin can increase heart contractility and aerobic respiration in T2D patients using GLS and iCPET measurements. Empagliflozin was shown to have a neutral impact on aerobic fitness and left ventricle (LV) systo-diastolic functions. The data suggests SGLT2 inhibitors can directly affect myocardial contractility in selected patients with subclinical LV systolic dysfunction, possibly justifying their benefit in HF primary prevention.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Lorenzo Nesti
University of Pisa
Pisa, Italy
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
